Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × lanreotide × Clear all

Phase

Status

Completed 12 Recruiting 5 Unknown 4 Terminated 4 Withdrawn 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Serotonin Syndrome 1 Carcinoid Heart Disease 1

Interventions

Cyclophosphamide 103 Radiotherapy 102 Cisplatin 100 pembrolizumab 94 Paclitaxel 76 Carboplatin 75 Gemcitabine 72 Nivolumab 68 Magnetic Resonance Spectroscopy 66 Fluorouracil 64 Dexamethasone 58 Bevacizumab 57 Radiosurgery 53 Docetaxel 53 Rituximab 48 Oxaliplatin 48 Leucovorin 48 fludarabine 45 Capecitabine 45 Biopsy 45 Doxorubicin 39 durvalumab 37 Drug Therapy 37 fludarabine phosphate 35 Etoposide 35 Cytarabine 35 Pemetrexed 34 Radiation 33 Lenalidomide 32 Specimen Handling 30

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04065165 2020-02-05

TELEFIRST

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Withdrawn

Carcinoid Heart Disease, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡